Allen & Overy advises ABF Ingredients on the acquisition of Fytexia Group
Related people
Press contacts
For media enquiries relating to this topic, please contact:
04 February 2022
Allen & Overy LLP has advised ABF Ingredients (ABFI) in relation to the acquisition from various sellers (including ArchiMed), of Fytexia Group, a life science company developing scientifically supported active nutrients for dietary supplements. This strategic acquisition will expand ABFI’s portfolio of products and capabilities to better serve the pharmaceutical, nutritional and food market sectors.
Headquartered in France, with a strong presence in Europe and regional offices in the US and Asia, Fytexia Group serves customers globally. Fytexia Group focuses on the research and scientific validation of bioactive compounds to deliver functional ingredients for the improvement of human health and wellbeing, targeting non-communicable diseases.
Fytexia Group is comprised of two businesses, Fytexia, a global expert in polyphenols, and B Natural, the European leader for the extraction and refinement of brown propolis.
The A&O team which has advised ABFI on this transaction consisted of Frédéric Moreau (Partner) and Antoine Messent (Associate).
The team also included Claire Toumieux (Partner) and Camille Wattrelos (Associate) on employment law aspects, Luc Lamblin (Counsel) and Vianney Leroux (Associate) on public law aspects and related to the control of foreign investments, Clémence d'Almeida (Associate) on commercial law aspects, Marianne Delassaussé (Senior Consultant) on intellectual property aspects, Laurie-Anne Ancenys (Counsel) on IT and data protection aspects, Asha Sinha (Senior Associate) on banking law aspects, Antoine Gueche (Associate) on real estate law aspects, and Gaspard Neuhoff (Associate) on litigation aspects.
The A&O teams from the Milan and New York offices were also involved in the transaction.